- Home
- PRQR vs PROF Comparison
PRQR vs PROF Comparison
Compare PRQR & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- PROF
- Stock Information
- Founded
- PRQR 2012
- PROF N/A
- Country
- PRQR Netherlands
- PROF Canada
- Employees
- PRQR N/A
- PROF N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- PROF Medical/Dental Instruments
- Sector
- PRQR Health Care
- PROF Health Care
- Exchange
- PRQR Nasdaq
- PROF Nasdaq
- Market Cap
- PRQR 179.1M
- PROF 149.7M
- IPO Year
- PRQR 2014
- PROF N/A
- Fundamental
- Price
- PRQR $2.13
- PROF $6.09
- Analyst Decision
- PRQR Strong Buy
- PROF Strong Buy
- Analyst Count
- PRQR 8
- PROF 2
- Target Price
- PRQR $8.88
- PROF $11.50
- AVG Volume (30 Days)
- PRQR 362.3K
- PROF 41.3K
- Earning Date
- PRQR 08-07-2025
- PROF 08-07-2025
- Dividend Yield
- PRQR N/A
- PROF N/A
- EPS Growth
- PRQR N/A
- PROF N/A
- EPS
- PRQR N/A
- PROF N/A
- Revenue
- PRQR $21,212,711.00
- PROF $11,862,000.00
- Revenue This Year
- PRQR N/A
- PROF $71.17
- Revenue Next Year
- PRQR N/A
- PROF $134.25
- P/E Ratio
- PRQR N/A
- PROF N/A
- Revenue Growth
- PRQR 85.91
- PROF 75.01
- 52 Week Low
- PRQR $1.07
- PROF $3.90
- 52 Week High
- PRQR $4.62
- PROF $11.42
- Technical
- Relative Strength Index (RSI)
- PRQR 64.73
- PROF 53.12
- Support Level
- PRQR $1.89
- PROF $5.84
- Resistance Level
- PRQR $2.54
- PROF $6.24
- Average True Range (ATR)
- PRQR 0.14
- PROF 0.35
- MACD
- PRQR 0.01
- PROF -0.08
- Stochastic Oscillator
- PRQR 43.06
- PROF 21.19
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.